Clinical Trials Using Fludarabine Phosphate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Fludarabine Phosphate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 141

  • Cyclophosphamide, Fludarabine Phosphate, and Total Body Radiation, before Donor Stem Cell Transplant in Treating Participants with Blood Disorders and Blood Cancers

    This phase III trial studies how well cyclophosphamide, fludarabine phosphate, and total body radiation before donor stem cell transplant work in treating participants with blood disorders and blood cancers. Giving chemotherapy such as cyclophosphamide and fludarabine phosphate and total body radiation before a stem cell transplant helps stop the growth of cells in the bone marrow. When the healthy cells from a donor are infused into the participant, they may help the patient's bone marrow make stem cells, red blood cells, and platelets. The donated cells may also replace the patient's immune cells and help destroy any remaining cancer cells.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

  • LN-145 in Treating Patients with Relapsed or Refractory Ovarian Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

    This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) works in treating patients with ovarian cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by collecting and growing specialized white blood cells (called T-cells) that are collected from the patient's tumor. The T cells may specifically recognize, target, and kill the tumor cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • AntiCD19 Chimeric Antigen Receptor T-Cells and Chemotherapy in Treating Participants with Recurrent or Refractory CD19 Positive Non-Hodgkin Lymphoma

    This phase 1 trial studies the side effects and best dose of autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells (antiCD9 chimeric antigen receptor T-cells) when given together with chemotherapy in treating participants with CD19 positive non-Hodgkin lymphoma that has come back or that does not respond to treatment. Therapy with antiCD9 chimeric antigen receptor T-cells works by removing T cells from the blood and modifying them to be able to target cancer. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, and may work to suppress the immune system and allow antiCD9 chimeric antigen receptor T-cells to work better. Giving antiCD9 chimeric antigen receptor T-cells and chemotherapy may work better in treating participants with non-Hodgkin lymphoma.
    Location: 2 locations

  • Tocilizumab in Improving Graft-Versus-Host Disease and Early Side Effects in Patients with Blood Cancers Undergoing Umbilical Cord Blood Transplant

    This phase II trial studies how well tocilizumab works in improving graft-versus-host disease (GVHD) and early side effects in patients with blood cancers undergoing umbilical cord blood transplant. Giving chemotherapy and total-body irradiation before an umbilical cord blood transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called GVHD). Giving tocilizumab in addition to the standard approach for GVHD prevention after the transplant may stop this from happening.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Donor Stem Cell Transplant in Treating Younger Patients with Hematologic Malignancies or Myelodysplasia

    This phase I / II trial studies how well stem cell transplant from partially matched related donors works in treating younger patients with hematologic malignancies or myelodysplasia. Donor stem cell transplant is a procedure in which a patient receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. Ideally, patients undergoing donor stem cell transplant receive a stem cell graft from a matched sibling; however, less than 30% of patients will have such a donor. There is a high likelihood of being unable to identify a perfect matched unrelated donor. Stem cell transplant from a partially matched related donor may result in result in successful engraftment and rapid immune rebuilding while maintaining a low risk of graft versus host disease.
    Location: Nationwide Children's Hospital, Columbus, Ohio

  • Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients with Primary or Secondary Myelofibrosis

    This early phase I trial studies the side effects of combination chemotherapy, total body irradiation, and donor blood stem cell transplant in treating patients with primary or secondary myelofibrosis. Drugs used in chemotherapy, such as melphalan, fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil, and filgrastim work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving combination chemotherapy and total body irradiation before a donor blood stem cell transplant helps to stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Anti-CD19-ARTEMIS T Cells, Fludarabine Phosphate, and Cyclophosphamide in Treating Participants with CD19+ Relapsed or Refractory Non-Hodgkin's Lymphoma

    This phase I trial studies the side effects and best dose of anti-CD19-ARTEMIS T cells when given together with fludarabine phosphate and cyclophosphamide in treating participants with non-Hodgkin's lymphoma that has come back or isn't responding to treatment. In engineered T-cell therapy, T cells (part of the immune system) are removed from the body and genetically modified in a laboratory before being transferred back into the participant. These modified cells (anti-CD19-ARTEMIS T cells) may be better able to recognize and kill cancer cells by targeting a protein on the cancer cell surface called CD19 (found on tumor cells and on normal antibody producing cells). Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Anti-CD19-ARTEMIS T cells together with fludarabine phosphate and cyclophosphamide may work better in treating participants with non-Hodgkin's lymphoma.
    Location: Duke University Medical Center, Durham, North Carolina

  • HERV-E TCR Transduced CD8+ / CD34+ T-cells in Treating Patients with Metastatic Clear Cell Renal Cell Cancer

    This phase I trial studies the side effects of HERV-E TCR transduced CD8+ / CD34+ T-cells in treating patients with clear cell renal cell cancer that has spread to other places in the body. HERV-E is a viral molecule of the HERVs family that becomes active in cancer cells and has been found in the surface of kidney tumor cells (not in healthy human normal cells). The incorporation of HERV-E into lymphocytes (T cells) may enable the immune system to recognize and fight kidney cancer cells.
    Location: National Heart Lung and Blood Institute, Bethesda, Maryland

  • Thiotepa, Fludarabine Phosphate, and Melphalan Hydrochloride in Treating Patients with Blood Cancer Undergoing Donor Stem Cell Transplant

    This phase II trial studies how well thiotepa, fludarabine phosphate, and melphalan hydrochloride work in treating patients with blood cancer who are undergoing a donor stem cell transplant. Drugs used in chemotherapy, such as thiotepa, fludarabine phosphate, and melphalan hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients with Blood Cancer

    This phase II trial studies how well fludarabine phosphate, cyclophosphamide, total body irradiation, and donor stem cell transplant work in treating patients with blood cancer. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient’s immune cells and help destroy any remaining cancer cells.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Nivolumab, Ipilimumab, and Immunotransplant in Treating Participants with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    This phase Ib / II trial studies the side effects of nivolumab, ipilimumab, and immunotransplant and to see how well they work in treating participants with diffuse large B cell lymphoma that has come back (relapsed) or that isn't responding to treatment (refractory). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Immunotransplant is a treatment used to help the immune system fight diseases such as cancer. T cells are collected from a participant and then given back to the participant after "lymphodepleting" chemotherapy which helps the anti-tumor immune T cells preferentially expand to target and eliminate tumor cells. Giving ipilimumab and nivolumab with immunotransplant may help treat participants with diffuse large B cell lymphoma.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • A Phase I / II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

    The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory).
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Autologous CD19 / CD22 Chimeric Antigen Receptor T-cells and Chemotherapy in Treating Patients with Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia

    This phase I trial studies the side effects of autologous CD19 / CD22 chimeric antigen receptor T-cells when given together with chemotherapy, and to see how well they work in treating patients with CD19 positive diffuse large B-cell lymphoma or B acute lymphoblastic leukemia that has come back or does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19 / CD22 proteins. These proteins are commonly found on diffuse large B-cell lymphoma and B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving autologous CD19 / CD22 chimeric antigen receptor T-cells and chemotherapy may work better in treating patients with diffuse large B-cell lymphoma or B acute lymphoblastic leukemia.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Nivolumab, Tumor Infiltrating Lymphocytes, Chemotherapy, and Aldesleukin in Treating Patients with Recurrent or Stage IV Non-small Lung Cancer

    This pilot phase I trial studies the side effects of nivolumab, tumor infiltrating lymphocytes, chemotherapy, and aldesleukin in treating patients with non-small lung cancer that is stage IV or has come back after period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tumor infiltrating lymphocytes involve the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell. Lymphocytes protect the body from viral infections, help other cells fight bacterial and fungal infections, produce antibodies, fight cancers, and coordinate the activities of other cells in the immune system. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Aldesleukin may help the body respond to treatment on the immune system. Giving nivolumab, tumor infiltrating lymphocytes, chemotherapy, and aldesleukin may work better in treating patients with non-small lung cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

    This phase Ib / II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia that has come back or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, filgrastim and idarubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with combination chemotherapy may work better in treating patients with acute myeloid leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ex-Vivo Expanded and Activated Donor NK Cells and Hu14.18-IL2 in Treating Patients with Relapsed or Refractory Neuroblastoma

    This phase I trial studies the side effects of ex-vivo expanded and activated donor NK cells and hu14.18-IL2 in treating patients with neuroblastoma that has come back or does not respond to treatment. Expanded and activated donor NK cells may be able to kill the cancer cells better. Hu14.18-IL2 binds to NK cells and may be able to activate them, improving their ability to stay alive, multiply, and kill cancer cells. Giving ex-vivo expanded and activated donor NK cells and hu14.18-IL2 may work better in treating patients with neuroblastoma.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • 211^At-BC8-B10 before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

    This phase I / II trial studies the side effects and best dose of 211^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia. Radioactive substances, such as astatine-211, linked to monoclonal antibodies, such as BC8, can bind to cancer cells and give off radiation which may help kill cancer cells and have less of an effect on healthy cells before donor stem cell transplant.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Haploidentical Stem Cell Selection using Miltenyi CliniMACS CD34 Reagent System in Treating Participants with High-Risk Hematologic Disorders

    This phase I / II trial studies the side effects and how well haploidentical stem cells selected using Miltenyi CliniMACS CD34 reagent system works in treating participants with high-risk hematologic disorders. Stem cells selected using Miltenyi CliniMACS CD34 reagent system from a half-matched donor, may increase the number of cells given to participants during stem cell transplantation in combination with umbilical cord blood transplantation.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Unrelated and Partially Matched Related Donor Peripheral Blood Stem Cell Transplant with TCR alpha / beta+ T Cell and B Cell Depletion for the Treatment of Patients with Acquired or Inherited Bone Marrow Failure

    This trial studies how well unrelated and partially matched related donor blood stem cell transplant with TCR alpha / beta+ T cell and B cell depletion works for treating patients with acquired and inherited bone marrow failure. Cell transplants from an unrelated or partially matched related donor has a higher rate of complications. T cells within the donor cells may cause a complication called graft versus host disease (GVHD) where the transplanted cells from a donor can attack the body's normal cells. Using the CliniMacs device to remove alpha / beta T cells and B cells may reduce some of the complications of the transplant and decrease the time it takes for the new stem cells to establish a new immune system.
    Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

  • Donor Nicotinamide Expanded-Natural Killer Cells Followed by IL-2 in Treating Patients with Relapsed or Refractory Multiple Myeloma or CD20 Positive Non-Hodgkin Lymphoma

    This phase I trial studies the best dose of donor nicotinamide expanded-natural killer cells followed by IL-2 in treating patients with multiple myeloma or CD20 positive non-Hodgkin lymphoma that has come back or does not respond to treatment. Nicotinamide expanded-natural killer cells may improve the natural killer cell cancer killing ability and improve their ability to home into the tumor cells. Interleukins such as IL-2, are proteins made by white blood cells and other cells in the body and may help regulate immune response. Giving nicotinamide expanded-natural killer cells followed by IL-2 may work better in treating patients with multiple myeloma or non-Hodgkin lymphoma.
    Location: University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota

  • Autologous IC9-CAR19 T cells in Treating Patients with Recurrent Acute Lymphoblastic Leukemia

    This phase I trial studies the side effect of autologous inducible caspase 9 chimeric antigen receptor targeting CD19 antigen (iC9-CAR19) T cells in treating patients with acute lymphoblastic leukemia that has come back. IC9-CAR19 T cells combines antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances and by stopping them from growing. T cells are special infection fighting blood cells that can kill other cells, including cancer cells or cells that are infected.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Reduced Intensity Conditioning and Stem Cell Transplant in Treating Patients with Blood Cancer

    This phase II trial studies how well reduced intensity conditioning (a short course of chemotherapy) and stem cell transplant work in treating patients with blood cancer. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient’s immune cells and help destroy any remaining cancer cells. Giving reduced intensity conditioning and total body irradiation before a donor blood stem cell transplant helps to stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells with shorter recovery and fewer side effects.
    Location: University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota

  • Engineered Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies

    This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Using T cells specially selected from donor blood in the laboratory for transplant may stop this from happening.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ruxolitinib Phosphate and Chemotherapy Given before and after Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Myelofibrosis

    This pilot clinical trial studies the side effects and best dose of ruxolitinib phosphate when given together with chemotherapy before and after a donor stem cell transplant in treating patients with myelofibrosis. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate together with chemotherapy before and after a donor stem cell transplant may help stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient’s immune cells and help destroy any remaining cancer cells.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Fludarabine Phosphate, Busulfan, Rabbit Anti-thymocyte Globulin, Tacrolimus, and Methotrexate in Treating Participants with Blood Cancer Undergoing Stem Cell Transplant

    This pilot early phase I trial studies how well fludarabine phosphate, busulfan, rabbit anti-thymocyte globulin, tacrolimus, and methotrexate work in treating participants with blood cancer undergoing stem cell transplant. Drugs used in chemotherapy, such as fludarabine phosphate, busulfan, and methotrexate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rabbit anti-thymocyte globulin and tacrolimus may be an effective treatment for lowering the incidence of graft-versus-host disease caused by a transplant. Giving fludarabine phosphate, busulfan, rabbit anti-thymocyte globulin, tacrolimus, and methotrexate may work better in treating participants with blood cancer.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire